Continuous Cellsaver and Neurocognitive Decline Post Cardiac Surgery
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Patients having cardiac surgery to correct their heart disease may suffer a decline in mental and neurologic abilities. Passage of small particles of fat, tissue waste and air bubbles to the brain while on the heart-lung machine is thought to be one cause for decline in mental and neurologic abilities (the function of brain) after surgery.
The purpose of this study is to determine if replacement of cardiotomy suction (one part of the heart-lung machine) with the cell-saver (a different part of the heart-lung machine) during surgery will help to prevent a decline in mental and neurologic abilities after surgery. investigating 312 patients over 2 years,patients will be assigned randomly to either cardiotomy suction or cell-saver group. Patients will be given questionnaires before surgery, 6 weeks and 1-year after surgery. These questionnaires will assess memory, attention span, the ability to concentrate and the quality of life. Patients will also have a brief neurologic exam (physical examination to check mental state, reflexes, strength, and balance) before surgery, 3-5 days after surgery, 6 weeks and 1-year after surgery to determine any changes. Cell-saver separates red blood cells from tissue waste products and fat prior to returning blood back to the patient and may reduce the negative effects of particles of fat, tissue waste and air bubbles have on the brain. Potential benefits of cell-saver device when used during surgery may prevent the decrease in memory, attention span, and the ability to concentrate resulting in improved quality of life after surgery.
Objectives: The primary aim is to determine the effect of continuous flow cell-saver on short and long term neurocognitive function after cardiac surgery, measured by precise preoperative and postoperative psychometric and neurologic testing. Hypothesis: The primary hypothesis: Continuous flow cell-saver reduces postoperative neurocognitive decline following cardiac surgery. Methodology: 312 informed and consenting patients, age > 65 years, scheduled for coronary artery bypass graft surgery will be prospectively enrolled over a 2-year period. Patients will be randomly allocated to either the continuous flow cell-saver or conventional cardiotomy suction (controls). Neurological history and physical exam will be completed preoperatively, discharge, 6-weeks and 1-year after surgery. Transcranial Doppler scanning will be used for intraoperative monitoring of cerebral embolic load. Transesophageal echocardiography and epiaortic scanning will be employed to account for the severity of the aortic atheroma scores. Neurocognitive testing and quality of life assessment will be conducted preoperatively , 6-weeks and 1-year after surgery. Significance: The utilization of continuous flow cell-saver may reduce the negative effects of fat particles, tissue waste and air emboli have on brain.
| Condition | Intervention | Phase |
|---|---|---|
|
Heart Disease Neurocognitive Decline |
Device: Fresenius Cellsaver |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind Primary Purpose: Prevention |
| Official Title: | The Impact of Continuous Flow Cellsaver on Neurocognitive Decline After Cardiac Surgery |
- The primary aim is to determine the effect of continuous flow cell-saver on short and long term neurocognitive function after cardiac surgery, measured by preoperative and postoperative psychometric and neurologic testing.
- A secondary aim is to determine if the improvement in cognitive function is associated with improved quality of life after cardiac surgery.
| Estimated Enrollment: | 312 |
Eligibility| Ages Eligible for Study: | 60 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age > 65 years,
- elective CABG surgery
- signed informed consent
Exclusion Criteria:
- Severe kidney (creatinine > 2.5mg/dL and
- liver disease (bilirubin > 2 mg/dL)
- symptomatic cerebrovascular disease
- alcoholism
- psychiatric illness
- patients who are unable to read or who have less than a 7th grade education.
Contacts and Locations| Canada, Ontario | |
| Toronto General Hospital, University Health Network | |
| Toronto, Ontario, Canada, M5G 2C4 | |
| Principal Investigator: | George N Djaiani, MD | Toronto General Hospital, University Health Network |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00296985 History of Changes |
| Other Study ID Numbers: | UHN REB 01-0420-B, HSFO NA4915 |
| Study First Received: | February 23, 2006 |
| Last Updated: | October 8, 2009 |
| Health Authority: | Canada: Health Canada |
Keywords provided by University Health Network, Toronto:
|
Cardiac surgery Cellsaver Neurocognitive Function Neuronal Protection Quality of Life |
Additional relevant MeSH terms:
|
Heart Diseases Cardiovascular Diseases |
ClinicalTrials.gov processed this record on May 21, 2013